公开(公告)号：US08772299B2

公开(公告)日：2014-07-08

申请号：US13015717

申请日：2011-01-28

Applicant: Yonggil Kim ,  Nahmryune Cho ,  Yunhee Kim ,  Joon Heo ,  Seonmin Dong ,  Mi Kyung Ji ,  Man-Young Cha ,  Kiho Lee

Inventor： Yonggil Kim ,  Nahmryune Cho ,  Yunhee Kim ,  Joon Heo ,  Seonmin Dong ,  Mi Kyung Ji ,  Man-Young Cha ,  Kiho Lee

IPC: A61K31/496 ,  A61K31/5377

CPC classification number: A61K31/496 ,  A61K31/5377 ,  C07D231/54 ,  C07D233/58 ,  C07D235/08 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/14 ,  C07D285/135 ,  C07D295/088 ,  C07D295/096

Abstract: The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and a method of treating depression, anxiety and other conditions related to 5-HT1A receptor in a mammal.

Abstract translation: 本发明涉及新颖的哌嗪衍生物或其药学上可接受的盐，其制备方法，特别是5-羟色胺1A（5-羟色胺; 5-HT1A）受体的高结合，用于治疗和/或 预防抑郁和焦虑，包括有效量的哌嗪化合物，以及治疗哺乳动物中与5-HT1A受体有关的抑郁，焦虑和其它病症的方法。

公开(公告)号：US07985752B2

公开(公告)日：2011-07-26

申请号：US12474943

申请日：2009-05-29

Applicant: Yonggil Kim ,  Nahmryune Cho ,  Yunhee Kim ,  Joon Heo ,  Seonmin Dong ,  Mi Kyung Ji ,  Man-Young Cha ,  Kiho Lee

Inventor： Yonggil Kim ,  Nahmryune Cho ,  Yunhee Kim ,  Joon Heo ,  Seonmin Dong ,  Mi Kyung Ji ,  Man-Young Cha ,  Kiho Lee

IPC: C07D241/04 ,  C07D295/00 ,  A61K31/4965

CPC classification number: A61K31/496 ,  A61K31/5377 ,  C07D231/54 ,  C07D233/58 ,  C07D235/08 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/14 ,  C07D285/135 ,  C07D295/088 ,  C07D295/096

Abstract: The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and a method of treating depression, anxiety and other conditions related to 5-HT1A receptor in a mammal.

Abstract translation: 本发明涉及新颖的哌嗪衍生物或其药学上可接受的盐，其制备方法，特别是5-羟色胺1A（5-羟色胺; 5-HT1A）受体的高结合，用于治疗和/或 预防抑郁和焦虑，包括有效量的哌嗪化合物，以及治疗哺乳动物中与5-HT1A受体有关的抑郁，焦虑和其它病症的方法。

公开(公告)号：US20090298831A1

公开(公告)日：2009-12-03

申请号：US12474943

申请日：2009-05-29

Applicant: Yonggil Kim ,  Nahmryune Cho ,  Yunhee Kim ,  Joon Heo ,  Seonmin Dong ,  Mi Kyung Ji ,  Man-Young Cha ,  Kiho Lee

Inventor： Yonggil Kim ,  Nahmryune Cho ,  Yunhee Kim ,  Joon Heo ,  Seonmin Dong ,  Mi Kyung Ji ,  Man-Young Cha ,  Kiho Lee

IPC: A61K31/5377 ,  C07D241/04 ,  C07D413/00 ,  C07D417/00 ,  C07D403/02 ,  A61K31/4965 ,  A61K31/497

CPC classification number: A61K31/496 ,  A61K31/5377 ,  C07D231/54 ,  C07D233/58 ,  C07D235/08 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D261/14 ,  C07D285/135 ,  C07D295/088 ,  C07D295/096

Abstract: The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and a method of treating depression, anxiety and other conditions related to 5-HT1A receptor in a mammal.

Abstract translation: 本发明涉及新颖的哌嗪衍生物或其药学上可接受的盐，其制备方法，特别是5-羟色胺1A（5-羟色胺; 5-HT1A）受体的高结合，用于治疗和/或 预防抑郁和焦虑，包括有效量的哌嗪化合物，以及治疗哺乳动物中与5-HT1A受体有关的抑郁，焦虑和其它病症的方法。

公开(公告)号：US10190093B2

公开(公告)日：2019-01-29

申请号：US15726672

申请日：2017-10-06

Applicant: Kiho Lee ,  Randall S. Prather

Inventor： Kiho Lee ,  Randall S. Prather

IPC: C12N5/00 ,  C12N5/02 ,  C12N15/00 ,  C12N5/075 ,  A01K67/027 ,  C12N15/877

Abstract: The present invention provides novel methods for improving the efficiency of artificial activation of unfertilized mammalian oocytes by reducing the intracellular concentration of Zn2+ in the oocyte. The methods of the invention may additionally comprise a preceding step of increasing the intracellular concentration of Ca2+ in the oocyte prior to reduction of the intracellular Zn2+ concentration. The invention further provides unfertilized oocytes activated by the disclosed methods and viable mammalian animals produced from unfertilized oocytes activated by the disclosed methods.

公开(公告)号：US09783779B2

公开(公告)日：2017-10-10

申请号：US14554504

申请日：2014-11-26

Applicant: Kiho Lee ,  Randall S. Prather

Inventor： Kiho Lee ,  Randall S. Prather

IPC: C12N5/00 ,  C12N5/02 ,  C12N15/00 ,  C12N5/075 ,  A01K67/027 ,  C12N15/877

CPC classification number: C12N5/0609 ,  A01K67/0273 ,  A01K2227/108 ,  C12N15/877 ,  C12N15/8778 ,  C12N2500/14 ,  C12N2500/22 ,  C12N2501/405 ,  C12N2517/04 ,  C12N2517/10

Abstract: The present invention provides novel methods for improving the efficiency of artificial activation of unfertilized mammalian oocytes by reducing the intracellular concentration of Zn2+ in the oocyte. The methods of the invention may additionally comprise a preceding step of increasing the intracellular concentration of Ca2+ in the oocyte prior to reduction of the intracellular Zn2+ concentration. The invention further provides unfertilized oocytes activated by the disclosed methods and viable mammalian animals produced from unfertilized oocytes activated by the disclosed methods.

公开(公告)号：US20150150153A1

公开(公告)日：2015-05-28

申请号：US14554504

申请日：2014-11-26

Applicant: Kiho Lee ,  Randall S. Prather

Inventor： Kiho Lee ,  Randall S. Prather

IPC: C12N5/075 ,  C12N15/877 ,  A01K67/027

CPC classification number: C12N5/0609 ,  A01K67/0273 ,  A01K2227/108 ,  C12N15/877 ,  C12N15/8778 ,  C12N2500/14 ,  C12N2500/22 ,  C12N2501/405 ,  C12N2517/04 ,  C12N2517/10

Abstract: The present invention provides novel methods for improving the efficiency of artificial activation of unfertilized mammalian oocytes by reducing the intracellular concentration of Zn2+ in the oocyte. The methods of the invention may additionally comprise a preceding step of increasing the intracellular concentration of Ca2+ in the oocyte prior to reduction of the intracellular Zn2+ concentration. The invention further provides unfertilized oocytes activated by the disclosed methods and viable mammalian animals produced from unfertilized oocytes activated by the disclosed methods.

Abstract translation: 本发明提供了通过降低卵母细胞中Zn 2+的细胞内浓度来提高未受精哺乳动物卵母细胞人工活化效率的新方法。 本发明的方法还可以包括在细胞内Zn 2+浓度降低之前增加卵母细胞中Ca 2+的细胞内浓度的前述步骤。 本发明还提供了通过所公开的方法活化的未受精的卵母细胞和由所公开的方法激活的未受精的卵母细胞产生的活的哺乳动物。

公开(公告)号：US20090298851A1

公开(公告)日：2009-12-03

申请号：US12128999

申请日：2008-05-29

Applicant: Yonggil Kim ,  Kiho Lee ,  Nahmryune Cho ,  Jin Uk Yoo ,  Joon Heo ,  Choonho Ryu ,  Seonmin Dong ,  Man-Young Cha ,  Jong Gil Choi ,  Yunhee Kim ,  Mi Kyung Ji

Inventor： Yonggil Kim ,  Kiho Lee ,  Nahmryune Cho ,  Jin Uk Yoo ,  Joon Heo ,  Choonho Ryu ,  Seonmin Dong ,  Man-Young Cha ,  Jong Gil Choi ,  Yunhee Kim ,  Mi Kyung Ji

IPC: A61K31/495 ,  C07D241/04 ,  A61P25/00

CPC classification number: C07D295/088 ,  C07D295/096

Abstract: The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effective amount of the piperazine compound and a method of treating central nervous system (CNS) disorder such as psychosis in a mammal.

Abstract translation: 本发明涉及一种新的哌嗪衍生物或其药学上可接受的盐，其制备方法，用于治疗中枢神经系统疾病的药物组合物，其包含有效量的哌嗪化合物和治疗中枢神经系统（CNS）的方法， 疾病如精神病在哺乳动物中。